The Lymphoma Academic Research Organisation

This Phase 3 trial tested an oral chemotherapy drug, azacitidine, against standard treatments in 86 patients with a rare type of T-cell lymphoma that had returned or not responded to prior therapy. The main goal was to see if the oral drug could delay cancer progression. The stud…

This study tested a drug called glofitamab in 67 people with certain types of lymphoma (a blood cancer) that did not respond to or came back after CAR T-cell therapy. Participants received a pre-treatment followed by up to 11 cycles of glofitamab. The goal was to see if this anti…

This study tested a combination of the drug pixantrone plus three other medicines (rituximab, ifosfamide, and etoposide) in 74 adults with a fast-growing type of lymphoma that had returned or not responded to treatment. The goal was to see how many patients had their tumors shrin…

This phase 2 trial tested whether adding the targeted drug obinutuzumab to standard chemotherapy (DHAP) and stem cell transplant could better control mantle cell lymphoma in 86 previously untreated patients. Participants received obinutuzumab during induction, before transplant, …

This study tested whether a combination of two drugs (rituximab and lenalidomide) works better than standard chemotherapy plus rituximab for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,030 adults with advanced disease who needed treatment took …